Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.

@article{Eitel2013NovelOA,
  title={Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.},
  author={Charlotte Eitel and Julia K Koch and Philipp Sommer and Silke John and Simon Kircher and Andreas Bollmann and Arash Arya and Christopher Piorkowski and Gerhard Hindricks},
  journal={Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology},
  year={2013},
  volume={15 11},
  pages={1587-93}
}
AIMS Experiences with novel oral anticoagulants (NOACs) early after atrial fibrillation (AF) catheter ablation are limited and show controversial results. We aimed to assess the longer-term safety, efficacy, and acceptance of NOACs in a large real-world cohort of patients presenting for AF catheter ablation. METHODS AND RESULTS From July 2010 until June 2012, 259 patients undergoing AF catheter ablation were prospectively included. Novel oral anticoagulants were given for at least 3 months… CONTINUE READING